Clinical Insights on R/R Follicular Lymphoma: ASH 2024 Highlights - Episode 9

ASH 2024 CAR T and Bispecifics Updates: Key Insights and Practical Considerations in 3L R/R FL Treatment

February 1, 2025

Panelists discuss key highlights from American Society of Hematology (ASH) 2024 updates on long-term follow-ups across chimeric antigen receptor (CAR) T trials and a matching-adjusted indirect comparison (MAIC) of outcomes with liso-cel, axi-cel, and tisa-cel, sharing their impressions of the MAIC data and their influence on day-to-day decision-making.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Treatment Strategies in 2L R/R FL: When to Treat vs Observe in Relapsed Disease

EP. 2: Clinical Perspectives Selecting 2L Treatment Options in R/R FL: Chemoimmunotherapy vs Lenalidomide Combinations in Relapsed Disease

EP. 3: ASH 2024 Updates: inMIND study With Tafasitamab Combined With Lenalidomide and Rituximab in R/R FL

EP. 4: Expert Insights: How Tafasitamab + R2 May Impact Clinical Practice in R/R FL

EP. 5: Exploring Tafasitamab in 2L Treatment: Challenges, Impact on Decision-Making, and Key Insights From inMIND Study

EP. 6: ASH 2024 Updates: EPCORE NHL-2 Trial With Fixed-Duration Epcoritamab + R2

EP. 7: Differentiating Treatment Options: Epcoritamab + R2 vs Tafasitamab-Lenalidomide-Rituximab in R/R FL

EP. 8: Choosing Bispecifics in 3L Treatment Setting R/R FL

Now Viewing

EP. 9: ASH 2024 CAR T and Bispecifics Updates: Key Insights and Practical Considerations in 3L R/R FL Treatment

EP. 10: Navigating the Evolving Treatment Landscape in R/R FL: When to Consider BTK and EZH2 Inhibitors

EP. 11: Expert Perspectives: Sequencing Tafasitamab + R2 With Currently Available Options in 3L Setting

EP. 12: Reflecting on 2024: Key Achievements and Looking Ahead to 2025 in R/R FL Treatment

Video content above is prompted by the following:

There have been several ASH 2024 updates, including the longer-term follow-ups across the CAR T trials as well as a MAIC of outcomes with liso-cel vs axi-cel vs tisa-cel. Dr Strati, could you review key highlights of these updates and your impressions of the MAIC data? Do MAIC data influence your day-to-day decision-marking?